Catalog No.: PC-35136Not For Human Use, Lab Use Only.
Zunsemetinib (ATI-450, CDD-450) is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 (MAPKAPK2, MK2) while sparing p38α activation of PRAK and ATF2.
Zunsemetinib (ATI-450, CDD-450) is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 (MAPKAPK2, MK2) while sparing p38α activation of PRAK and ATF2.
Zunsemetinib (ATI-450) is an orally bioavailable small molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2) pathway.
Zunsemetinib (ATI-450, CDD-450) shows no effect on NLRP3 expression, but decreases IL-1β expression by promoting IL-1β mRNA degradation.
Zunsemetinib (ATI-450, CDD-450) accelerates TNF-α and IL-6 mRNA decay, inhibites inflammation in mice with cryopyrinopathy, and is as efficacious as global p38α inhibitors in attenuating arthritis in rats and cytokine expression by cells from patients with cryopyrinopathy and rheumatoid arthritis.
